Aggressive B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Aggressive B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab and tazemetostat to overcome immune tolerance after ASCT or CAR-T therapy in patients with a…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 3]
A Phase 3 clinical trial comparing Mosunetuzumab in combination with Polatuzumab Vedotin against Rituximab in combination with Gemcitabine p…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractor…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial is evaluating high-dose therapy with autologous stem cell transplant followed by infusion of CD19-directed CAR-T ce…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial sponsored by Celgene evaluating lisocabtagene maraleucel (JCAR017) in adults with aggressive B-cell non-Hodgkin lymphoma has…
-
CLINICAL_TRIALS trial_result · 2022-06-08Clinical Trial Update: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia [Phase 3]
A Phase 3 trial comparing lipegfilgrastim to pegfilgrastim in elderly patients with aggressive B-cell non-Hodgkin lymphoma at high risk of R…
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial update evaluating pegfilgrastim with combination chemotherapy, with or without rituximab, in older patients with aggressive B-…
-
CLINICAL_TRIALS trial_result · 2020-06-02Clinical Trial Update: Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger [Phase 2]
Phase 2 trial comparing Rituximab-HCVAD alternating with Rituximab-Methotrexate-Cytarabine vs Rituximab-CHOP in newly diagnosed high-risk ag…
-
CLINICAL_TRIALS trial_result · 2012-04-12Clinical Trial Update: A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant [EARLY_Phase 1]
An early-phase (Phase 1) pilot study evaluating dose-escalating RICE chemotherapy plus bortezomib for relapsed or primary refractory aggress…